Feroscan was set up in 2014 at the initiative of its four founders, bringing together scientific and business skills. Feroscan specializes in the development of first-in-class personalized cytotoxics with a unique and innovative mode of action. The pipeline of the company focuses on intractable cancers; such as ovarian and triple negative breast cancers.
¹ó±ð°ù´Ç²õ³¦²¹²Ô’s business strategy is to test in parallel several preclinical programs on several orphan applications up to proof of concept, IND and early clinical stages. Feroscan is based on a strong IP strategy, cutting edge science and connects to a strong academic and industrial network worldwide to develop clinical applications of its research programs.
Original establishment: ENSCP - PSL, Sorbonne University, CNRS
Founder: Gérard Jaouen
CEO: Franck Pradier
Director: Professor G. Jaouen
